A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting

PURPOSE: Despite triple antiemetic therapy use for breast cancer patients receiving emetogenic chemotherapy, nausea remains a clinical challenge. We evaluated adding olanzapine (5 mg) to triple therapy on nausea control in patients at high personal risk of chemotherapy-induced nausea and vomiting (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemons, M., Dranitsaris, G., Sienkiewicz, M., Sehdev, S., Ng, T., Robinson, A., Mates, M., Hsu, T., McGee, S., Freedman, O., Kumar, V., Fergusson, D., Hutton, B., Vandermeer, L., Hilton, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695916/
https://www.ncbi.nlm.nih.gov/pubmed/33242754
http://dx.doi.org/10.1016/j.breast.2020.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695916/
https://www.ncbi.nlm.nih.gov/pubmed/33242754
http://dx.doi.org/10.1016/j.breast.2020.11.002

Ejemplares similares